/Stocks/PFE
▲ Cast your call
PFEPfizer Inc. · NYSE · Healthcare
$25.90$-0.05 · -0.19%
MKT 147.25B

Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers - General
Phone
212 733 2323
Headquarters
66 Hudson Boulevard East
New York, NY, 10001-2192
United States
Full-Time Employees
75,000

Key Metrics

P/E Ratio (TTM)
19.72
Forward P/E
9.10
Price to Book
1.70
Beta
0.31
Profit Margin
11.83%
Gross Margin
74.80%
Return on Equity
8.31%
Return on Assets
5.69%
Earnings Growth
-10.10%
Revenue Growth
5.40%
Dividend Yield
663.00%
Dividend Rate
$1.72

Financial Health

Total Cash
$13.08B
Total Debt
$64.73B
Debt to Equity
71.60
Current Ratio
1.25
Free Cash Flow
$12.38B
Operating Cash Flow
$11.98B

Analyst Recommendations

Target Price (Mean)
$29.19
Target High
$36.00
Target Low
$24.00
Recommendation
buy
Analyst Coverage
27 Analysts

Trading Ideas

Related Stocks

Will PFE Beat Earnings? AI Prediction next earnings | CallTheBeat